Here is what you need to know on Monday, September 14:
AstraZeneca's renewal of its coronavirus vaccine test is contributing to a better market mood, favorable for stocks and weighing on the dollar. Japan will have a new prime minister and the UK parliament will debate the controversial internal market bill today, aggravating relations with the EU.
Upbeat mood: The University of Oxford and AstraZeneca will restart their COVID-19 immunization Phase 3 trial in the UK. Pfizer, a larger pharma firm, said that a coronavirus vaccine could be given to Americans before year-end.
S&P 500 futures are on the rise while the dollar is losing ground against most currencies. Gold has been trading in a range around $1,950.
Japan: Cabinet Secretary Yoshihide Suga will likely be elected by the ruling LDP Party to succeed outgoing Prime Minister Shinzo Abe. He is seen as a continuation candidate. The yen is marginally higher amid broad dollar weakness.
GBP/USD is licking its wounds around 1.28, hit by the escalation in the EU-UK relations. The House of Commons will debate the controversial Internal Market Bill on Monday, which breaks international law and angered the bloc. Brussels announced that if the bill is not rescinded by the end of the month, it would slap sanctions.
EUR/USD is on the rise despite rising COVID-19 cases in the old continent. Several members of the European Central Bank reiterated their stance that the euro's value impacts inflation but that the ECB does not target it.
Sino-American tensions: Microsoft's bid to purchase TikTok was rejected, leaving Oracle as the sole contender to buy the popular Chinese video application. It is unclear if the administration would approve the deal.
Oil prices have stabilized after the fall. OPEC and non-OPEC members will convene later in the week to discuss extending production cuts. Compliance has been relatively high yet fears of falling demand persist. Hurricanes are brewing in the Gulf of Mexico and could boost crude prices.
Cryptocurrencies are edging higher, with Bitcoin holding above $10,000 after retreating from the highs last week.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.